SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis

Reuters

2025/07/14

SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis

SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551902500"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551902500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551902500?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551902500","market":"fut","top_or_hot":-1,"title":"SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-14 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL9hp38S:1","article_id":"2551902500","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551902500","pubTimestamp":1752487544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 , for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","03681":"中国抗体-B","BK1574":"生物医药B类股"},"translate_title":"SinoMab BioScience Ltd.宣布正在对SM03（Suciraslimab）治疗类风湿性关节炎进行监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":0.9},"content_text":"SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n    \n\n        SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}